Home/Company News

< Back to News & Events

Minneapolis Star Tribune: VivaQuant is making an intriguing bet on equity crowdfunding

VivaQuant is not anything like the dozen or so Minnesota businesses that have sought funding directly from small investors in the last few years, a list dominated by small craft brewers. VivaQuant doesn’t aspire to be a successful small business.

2019-05-22T19:50:01-05:00May 19th, 2019|Company News|

VivaQuant algorithm shows 6-fold reduction in risk classification error relative to FDA published results

This study demonstrates that fully automated continuous beat to beat measurements over 24 hours can be obtained using the Rhythm Express software and used to discriminate multichannel ion block from pure hERG block.

2019-05-22T19:51:43-05:00November 10th, 2018|Company News, Publications|

VivaQuant Inks Collaboration with FDA to Improve Accuracy of Drug Cardiac Safety Assessment

VivaQuant has entered into a five-year collaboration with the FDA to research ways to improve cardiac safety assessment of medications. In this project, VivaQuant's advanced ECG processing tools will be used to derive continuous beat-to-beat measurements of cardiac electrical waves from preclinical and clinical ECG studies.

2019-05-22T19:52:44-05:00October 19th, 2018|Company News|

VivaQuant Technology Shows Promise for Improving Drug Safety Assessment Accuracy

VivaQuant MDSP technology was the subject of a recent manuscript published in The Journal of Pharmacological and Toxicological Methods (JPTM) titled "Comparison of one- and three-lead ECG to measure cardiac intervals and differentiate drug-induced multi-channel block".

2019-05-22T19:53:52-05:00June 11th, 2018|Company News, Publications|

WEBINAR: Improving Preclinical and Clinical Regulatory Submissions Through Enhanced ECG Interval and Arrhythmia Assessment

Experts in preclinical and clinical ECG safety assessment discuss how advances in arrhythmia detection and concentration effects modelling improve study outcomes.

2019-05-22T19:55:12-05:00March 11th, 2018|Company News, Events, Webinars|

VivaQuant Rhythm Express software demonstrates improved accuracy of cardiac safety assessment markers

Fully automated QT measurements, obtained from VivaQuant Rhythm Express software, with no human review or editing, were shown to improve accuracy of concentration effect models used in drug safety assessment by 22 percent

2019-05-22T19:55:52-05:00November 21st, 2017|Company News, Publications|

VivaQuant and DSI Announce Agreement

Arrangement allows researchers to use the unique VivaQuant algorithms on ECG signals acquired by DSI telemetry and wired acquisition technologies.

2019-05-22T19:56:32-05:00September 11th, 2017|Company News|

VivaQuant Releases AE-1010 Rhythm Express Software

The AE-1010 software provides powerful features and performance for fast, accurate, and efficient analysis and insightful reporting of ECG arrhythmias and intervals in pharmaceutical and medical device research

2019-05-22T19:57:17-05:00March 7th, 2017|Company News|

VivaQuant Celebrates Eight Years of Success

VivaQuant is celebrating eight years since its founding. In those eight years, VivaQuant is proud to have accomplished these significant milestones...

2019-05-22T19:58:08-05:00February 9th, 2017|Company News|